Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Bladder Cancer

Free Subscription Articles published in Int Urol Nephrol Retrieve available abstracts of 104 articles: HTML format

Single Articles

October 2026
1. PETRELLI F, Ghidini A, Vavassori I, Rossitto M, et al
   Early versus deferred immunotherapy in urothelial carcinoma: a review of evidence and post-progression survival.
   Int Urol Nephrol. 2026;58:3969-3976.
   PubMed     Abstract available
   
   
   September 2026
2. YAJIMA S, Yoshida S, Chen W, Fukushima H, et al
   Time-dependent effects of BCG plus immune checkpoint inhibitors in BCG-naive high-risk non-muscle-invasive bladder cancer: a reconstructed patient-level analysis.
   Int Urol Nephrol. 2026 Sep 4. doi: 10.1007/s11255-026-05373.
   PubMed     Abstract available
   
   
   
3. YOUSSEF HMK, Ibrahim EH, Hasan A, Samman A, et al
   Immunohistochemical assessment of vimentin expression and Ki-67 proliferation index in conventional urothelial carcinoma: a study of 60 Egyptian patients.
   Int Urol Nephrol. 2026;58:3557-3566.
   PubMed     Abstract available
   
   
   
4. BAKHSH A, Abdullah S, Farghal DM, Badawi AS, et al
   Association of electronic cigarette and conventional smoking with urogenital cancers: NHIS analysis.
   Int Urol Nephrol. 2026;58:3681-3688.
   PubMed     Abstract available
   
   
   August 2026
5. CHEN Y, An W, Qu R, Chen C, et al
   Bladder preservation with disitamab vedotin plus PD-1 inhibitors and local intensification in muscle-invasive bladder cancer: a single-center retrospective cohort of 81 patients.
   Int Urol Nephrol. 2026 Aug 28. doi: 10.1007/s11255-026-05316.
   PubMed     Abstract available
   
   
   
6. CHAI Y, Zhang L, Zhou Y, Dai J, et al
   Concurrent radiosensitising regimens for bladder-preserving radiotherapy in non-metastatic muscle-invasive bladder cancer: a systematic review and structured evidence synthesis with exploratory network meta-analysis.
   Int Urol Nephrol. 2026 Aug 26. doi: 10.1007/s11255-026-05360.
   PubMed     Abstract available
   
   
   
7. RYTZ MA, Hussung S, Frehner L, Beyer J, et al
   LRRC8A as a candidate biomarker of cisplatin sensitivity in muscle-invasive bladder cancer: an exploratory immunohistochemical study.
   Int Urol Nephrol. 2026 Aug 25. doi: 10.1007/s11255-026-05351.
   PubMed     Abstract available
   
   
   July 2026
8. ZHANG B, Wang C, Yang S, Li X, et al
   A comparison of efficacy and prognosis between RC48 combined immunotherapy and gemcitabine-cisplatin combined immunotherapy in bladder-preserving multimodal therapy for muscle-invasive bladder cancer.
   Int Urol Nephrol. 2026 Jul 25. doi: 10.1007/s11255-026-05275.
   PubMed     Abstract available
   
   
   
9. GAO M, Liu F, Wen J, Shen Y, et al
   Beyond VI-RADS: incremental value of quantitative mpMRI measurements for identifying muscle-invasive bladder cancer.
   Int Urol Nephrol. 2026 Jul 10. doi: 10.1007/s11255-026-05267.
   PubMed     Abstract available
   
   
   
10. WANG Y, Zhao T, Liang B, Zhen L, et al
    Multiparametric MRI-derived radiomic signatures enable noninvasive prediction of HER2 expression in bladder cancer.
    Int Urol Nephrol. 2026 Jul 3. doi: 10.1007/s11255-026-05256.
    PubMed     Abstract available
    
    
    
11. CONTIERI R, Jannello LMI, Vartolomei MD, Roth B, et al
    Defining the optimal duration of maintenance mitomycin C in intermediate-risk Ta NMIBC: a multicenter retrospective landmark analysis.
    Int Urol Nephrol. 2026;58:2463-2471.
    PubMed     Abstract available
    
    
    
12. DENG S, Jiang R, Wu S, Xiao Y, et al
    Bladder tumors in patients initially diagnosed with interstitial cystitis: a ten-year retrospective study.
    Int Urol Nephrol. 2026;58:2503-2511.
    PubMed     Abstract available
    
    
    
13. SANDBERG M, Thole D, Bissette R, Wolff D, et al
    Comparing benign to malignant cystectomy: complications, emergency department utilization, readmissions, and socioeconomic status.
    Int Urol Nephrol. 2026;58:2429-2436.
    PubMed     Abstract available
    
    
    June 2026
14. MCMASTER T, Hoskin G, Homewood D, Attwell-Heap A, et al
    A comparative analysis of variant histology and urothelial bladder cancer following radical cystectomy.
    Int Urol Nephrol. 2026 Jun 10. doi: 10.1007/s11255-026-05234.
    PubMed     Abstract available
    
    
    May 2026
15. SAKTHIVEL DK, Prabhakar P, Raja Iyub MJ, Garje R, et al
    Signet ring cell carcinoma of the urachus: survival and pathologic outcomes from the national cancer database.
    Int Urol Nephrol. 2026;58:1745-1751.
    PubMed     Abstract available
    
    
    April 2026
16. RUSSO P, Foschi N, Lentini N, Bizzarri FP, et al
    Perioperative outcomes following open radical cystectomy in the setting of locally advanced bladder cancer.
    Int Urol Nephrol. 2026 Apr 9. doi: 10.1007/s11255-026-05127.
    PubMed     Abstract available
    
    
    
17. TANG C, Wang T, Luo H, Xue J, et al
    Liquid biopsy based on multi-targeted capture of urinary tumor DNA combined with machine learning to detect urothelial carcinoma: a multicenter prospective study.
    Int Urol Nephrol. 2026;58:1291-1306.
    PubMed     Abstract available
    
    
    March 2026
18. GUO C, Wei J, Wang Y, Zhang L, et al
    Stage-specific associations of HER2 overexpression with clinical and pathological features in bladder cancer: a systematic review and meta-analysis.
    Int Urol Nephrol. 2026 Mar 25. doi: 10.1007/s11255-026-05110.
    PubMed     Abstract available
    
    
    
19. SRIVASTAVA A, Trivedi S, Singh Y, Kumar U, et al
    Prospective comparative evaluation of clinical efficacy and safety of Intravesical gemcitabine-docetaxel versus BCG in adjuvant management of BCG-naive non-muscle invasive urothelial bladder cancer in Indian population.
    Int Urol Nephrol. 2026 Mar 17. doi: 10.1007/s11255-026-05067.
    PubMed     Abstract available
    
    
    
20. ZHENG Q, Liao E, Chen D, Shan G, et al
    Bladder cancer organoids: bridging pathological features and drug response for precision oncology.
    Int Urol Nephrol. 2026 Mar 8. doi: 10.1007/s11255-026-05081.
    PubMed     Abstract available
    
    
    
21. PELLEGRINO P, Scherer TP, Wettstein MS, Baumgartner M, et al
    Development of a nomogram for prediction of postoperative bleeding after transurethral resection of bladder tumors.
    Int Urol Nephrol. 2026;58:921-929.
    PubMed     Abstract available
    
    
    
22. NISHIMURA F, Oniki K, Yamashita A, Honda K, et al
    Prognostic role of intramuscular adipose tissue content in patients with urothelial carcinoma treated with pembrolizumab.
    Int Urol Nephrol. 2026;58:861-871.
    PubMed     Abstract available
    
    
    January 2026
23. OZDEN SB, Bulbul E, Ilki Y, Vural A, et al
    Effect of frailty status and histopathological features on upstaging of non-muscle-invasive bladder cancer: a critical analysis based on machine learning.
    Int Urol Nephrol. 2026 Jan 26. doi: 10.1007/s11255-026-05021.
    PubMed     Abstract available
    
    
    
24. AYKAC A, Kaya C, Sungur M, Aydin ME, et al
    Holmium laser en?bloc vs bipolar and conventional monopolar TURBT for non?muscle?invasive bladder cancer.
    Int Urol Nephrol. 2026 Jan 24. doi: 10.1007/s11255-026-05023.
    PubMed     Abstract available
    
    
    
25. CHAI Y, Zhou Y, Peng H, Jiang Y, et al
    Comparative efficacy of hyperthermic chemotherapy and BCG instillation in non-muscle invasive bladder cancer: a systematic review and meta-analysis.
    Int Urol Nephrol. 2026 Jan 11. doi: 10.1007/s11255-026-05008.
    PubMed     Abstract available
    
    
    December 2025
26. ZHANG W, Wei Q, Han X, Zheng X, et al
    Global, regional, and national burdens of bladder cancer in individuals aged 60 years and older from 1990 to 2021: a cross-sectional study.
    Int Urol Nephrol. 2025 Dec 9. doi: 10.1007/s11255-025-04941.
    PubMed     Abstract available
    
    
    
27. SONG Z, Wang Y, Yu C, Sha K, et al
    ZSTK474 suppresses bladder cancer cell migration and invasion via PI3K/Akt/Girdin pathway: an in vitro study.
    Int Urol Nephrol. 2025 Dec 5. doi: 10.1007/s11255-025-04940.
    PubMed     Abstract available
    
    
    November 2025
28. RAJA IYUB MJ, Prabhakar P, Sakthivel DK, Chandrasekaran A, et al
    Metastatic non-muscle invasive bladder cancer: histology-specific metastatic patterns and survival in a national cancer database analysis.
    Int Urol Nephrol. 2025 Nov 11. doi: 10.1007/s11255-025-04907.
    PubMed     Abstract available
    
    
    October 2025
29. HONG T, Zhao C, Ji H, Chen H, et al
    Bladder-sparing therapy for high-tumor-burden non-muscle invasive bladder cancer: outcomes from high-tumor-burden NMIBC program.
    Int Urol Nephrol. 2025 Oct 28. doi: 10.1007/s11255-025-04873.
    PubMed     Abstract available
    
    
    
30. ZHANG T, Liu J, Feng L, Ke C, et al
    Prognostic prediction of incidental prostate cancer in radical cystoprostatectomy for muscle-invasive bladder cancer.
    Int Urol Nephrol. 2025 Oct 23. doi: 10.1007/s11255-025-04858.
    PubMed     Abstract available
    
    
    
31. YENTUR S, Canitez IO, Dusunus YE, Sahin S, et al
    Simultaneous transurethral resection of the prostate and bladder tumor: a safety and efficacy analysis.
    Int Urol Nephrol. 2025;57:3219-3226.
    PubMed     Abstract available
    
    
    September 2025
32. LIU X, Wang Y, Wang Z, Shao B, et al
    Chemotherapy-enhanced endoscopic submucosal En Bloc dissection vs. conventional TURBT for NMIBC: a comparative study.
    Int Urol Nephrol. 2025;57:2755-2765.
    PubMed     Abstract available
    
    
    August 2025
33. YILDIZ AK, Bayraktar A, Kacan T, Demir DO, et al
    Two different protocols in single, immediate, postoperative intravesical chemotherapy after transurethral resection in suspected, low-risk, non-muscle-invasive bladder cancer.
    Int Urol Nephrol. 2025 Aug 28. doi: 10.1007/s11255-025-04767.
    PubMed     Abstract available
    
    
    
34. XIANG X, Mei X, Song X, Pan B, et al
    High-density lectin microarray uncovers stage-specific plasma glycoprofiling signatures for non-muscle-invasive and muscle-invasive bladder cancer.
    Int Urol Nephrol. 2025 Aug 10. doi: 10.1007/s11255-025-04708.
    PubMed     Abstract available
    
    
    
35. IOSSA V, Olivieri A, Buonopane R, Di Girolamo A, et al
    Assessment of quality of life in patients undergoing hyperthermic intravesical chemotherapy (HIVEC) using EORTC questionnaires (QLQ-C30 and QLQ-NMIBC24).
    Int Urol Nephrol. 2025;57:2415-2423.
    PubMed     Abstract available
    
    
    July 2025
36. MANTICA G, Calarco A, Leonardi R
    Artificial intelligence for rare bladder cancer variants: a new hope for detection?
    Int Urol Nephrol. 2025 Jul 4. doi: 10.1007/s11255-025-04647.
    PubMed    
    
    
    
37. LI Y, Sun X, Wang Y, Ma B, et al
    Prognostic factors in T1 high-grade urothelial carcinoma of the bladder with lymphovascular invasion: a retrospective cohort study.
    Int Urol Nephrol. 2025;57:2099-2105.
    PubMed     Abstract available
    
    
    
38. GUBBIOTTI M, Rubilotta E, Bacchiani M, Cocci A, et al
    Intravesical administration of highly concentrated hyaluronic acid and chondroitin sulfate as add-on therapy for chemical cystitis induced by Bacillus Calmette-Guerin (BCG) immunotherapy.
    Int Urol Nephrol. 2025;57:2033-2039.
    PubMed     Abstract available
    
    
    June 2025
39. LI JKM, Wang L, Tse RTH, Leung CH, et al
    A cross-sectional study on the effects of intravesical BCG on urinary microbiota in bladder cancer patients.
    Int Urol Nephrol. 2025 Jun 30. doi: 10.1007/s11255-025-04607.
    PubMed     Abstract available
    
    
    
40. SOLTANI S, Rahimi HR, Mottaghi M, Tavakkoli M, et al
    Comparison of microRNA-21 expression in bladder cancer tumor with normal-appearing adjacent tissue and healthy controls.
    Int Urol Nephrol. 2025 Jun 13. doi: 10.1007/s11255-025-04581.
    PubMed     Abstract available
    
    
    
41. MA W, Shui Y, Wang G, Zhang X, et al
    Previous maximal transurethral resection of bladder tumor lead to unfavorable perioperative outcomes following radical cystectomy.
    Int Urol Nephrol. 2025;57:1817-1826.
    PubMed     Abstract available
    
    
    May 2025
42. ZHANG S, Chen C, Mo C, Fan N, et al
    A clinical study of RC48-ADC combined with PD-1 inhibitor in bladder preservation therapy for muscle-invasive bladder cancer (MIBC)-based on real-world data analysis.
    Int Urol Nephrol. 2025 May 14. doi: 10.1007/s11255-025-04567.
    PubMed     Abstract available
    
    
    
43. LONGONI M, Marmiroli A, Falkenbach F, Le QC, et al
    Oncological outcomes after non-surgical management versus radical cystectomy in non-organ-confined non-urothelial bladder cancer.
    Int Urol Nephrol. 2025 May 7. doi: 10.1007/s11255-025-04566.
    PubMed     Abstract available
    
    
    
44. MAHRAN SE, Salem SE, Sabry NA, Farid SF, et al
    The nephroprotective effect of metformin with cisplatin in bladder cancer: randomized clinical trial.
    Int Urol Nephrol. 2025 May 3. doi: 10.1007/s11255-025-04505.
    PubMed     Abstract available
    
    
    
45. GAO S, Liu T, Liu Q
    DNMT1 promotes bladder cancer progression and immune escape by inhibiting MYH11 expression by methylating its promoter.
    Int Urol Nephrol. 2025 May 2. doi: 10.1007/s11255-025-04527.
    PubMed     Abstract available
    
    
    
46. PLAGE H, Furlano K, Hofbauer S, Rossner F, et al
    PLAP expression is linked to invasive tumor growth in urothelial carcinoma of the bladder.
    Int Urol Nephrol. 2025;57:1381-1388.
    PubMed     Abstract available
    
    
    April 2025
47. WONG TR, Sun C, Ledesma B, Isali I, et al
    The role of angiogenin in bladder cancer: where are we in 2025?
    Int Urol Nephrol. 2025 Apr 22. doi: 10.1007/s11255-025-04517.
    PubMed     Abstract available
    
    
    
48. WU YJ, Chang SJ, Huang YS, Chai CY, et al
    Overexpression of BMAL-1 is related to progression of urothelial carcinoma in arsenic exposure area.
    Int Urol Nephrol. 2025;57:1175-1187.
    PubMed     Abstract available
    
    
    March 2025
49. CHEN CC, Yen TH, Li JR, Chen CJ, et al
    Artificial intelligence algorithms enhance urine cytology reporting confidence in postoperative follow-up for upper urinary tract urothelial carcinoma.
    Int Urol Nephrol. 2025;57:801-808.
    PubMed     Abstract available
    
    
    February 2025
50. FAN H, Chen W, Guo W, Han J, et al
    Intravesical gemcitabine versus anthracyclines for primary and first recurrent non-muscle-invasive bladder cancer: a single-center retrospective study over 10 years.
    Int Urol Nephrol. 2025 Feb 21. doi: 10.1007/s11255-025-04413.
    PubMed     Abstract available
    
    
    
51. STROJNY Z, Kawka E, Strojny M, Kucz-Chrostowska A, et al
    Exploring the impact of chronotype, chrononutrition and lifestyle on bladder cancer.
    Int Urol Nephrol. 2025 Feb 21. doi: 10.1007/s11255-025-04371.
    PubMed     Abstract available
    
    
    
52. CONTIERI R, Guigui A, Gondran-Tellier B, Basile G, et al
    Key strategies for reducing recurrence in T1 bladder cancer. Evidence from a retrospective multicenter European study.
    Int Urol Nephrol. 2025 Feb 11. doi: 10.1007/s11255-025-04416.
    PubMed     Abstract available
    
    
    January 2025
53. ZHAO L, Tian G, Wang X, Li L, et al
    Clinical significance of a new early diagnostic model for bladder cancer based on genome-wide microarray profiling of serum exosomal lncRNAs.
    Int Urol Nephrol. 2025 Jan 7. doi: 10.1007/s11255-024-04360.
    PubMed     Abstract available
    
    
    
54. AKDAS EM, Culha MM, Telli E, Bosnali E, et al
    The effect of intravesical chemohyperthermia with mitomycin in non-muscle-invasive bladder tumour patients who cannot tolerate BCG treatment or recur after treatment and refuse cystectomy.
    Int Urol Nephrol. 2025;57:63-69.
    PubMed     Abstract available
    
    
    December 2024
55. SEVEN I, Akturk Esen S, Sekmek S, Karahan I, et al
    Clinicopathological features and treatment outcomes of urothelial carcinoma variant histologies and non-urothelial bladder cancers.
    Int Urol Nephrol. 2024 Dec 27. doi: 10.1007/s11255-024-04341.
    PubMed     Abstract available
    
    
    
56. KAYRA MV, Deniz ME, Ozer C, Guvel S, et al
    Estimation of Physiologic Ability and Surgical Stress (E-PASS) predicts postoperative complications after radical cystectomy.
    Int Urol Nephrol. 2024;56:3743-3749.
    PubMed     Abstract available
    
    
    November 2024
57. IVANIC D, Dug H, Jagodic S, Delibegovic S, et al
    Preoperative neutrophil-to-lymphocyte ratio (NLR) value as a predictor of recurrence of non-muscle-invasive bladder cancer.
    Int Urol Nephrol. 2024 Nov 27. doi: 10.1007/s11255-024-04297.
    PubMed     Abstract available
    
    
    August 2024
58. XIONG Y, Zhao T, Li C
    Application value of extreme flexion and abduction hip combined with stirrup-shaped multifunctional leg frame in blocking obturator nerve reflex in transurethral resection of bladder tumor.
    Int Urol Nephrol. 2024;56:2503-2511.
    PubMed     Abstract available
    
    
    
59. LUO Q, Xu L, Lin C, Chao H, et al
    The clinical study of urinary flow parameters after drag-and-bond anastomosis for ileal orthotopic neobladder reconstruction.
    Int Urol Nephrol. 2024;56:2615-2621.
    PubMed     Abstract available
    
    
    July 2024
60. LIANG H, Sun H, Chen J
    A modified ureteroileal anastomosis can reduce ureteroileal anastomotic stricture after ileal conduit.
    Int Urol Nephrol. 2024;56:2235-2241.
    PubMed     Abstract available
    
    
    
61. REFUGIA JM, Thakker PU, Roebuck E, Brownstead HA, et al
    Surgeon-administered regional nerve blocks during radical cystectomy: a feasibility study.
    Int Urol Nephrol. 2024;56:2227-2234.
    PubMed     Abstract available
    
    
    June 2024
62. DAVID J, Pathak RA
    Editorial comment for "Surgeon-administered regional nerve blocks during radical cystectomy: a feasibility study".
    Int Urol Nephrol. 2024;56:1937-1938.
    PubMed    
    
    
    May 2024
63. YAN T, Zhou W, Li C
    Discovery of a T cell proliferation-associated regulator signature correlates with prognosis risk and immunotherapy response in bladder cancer.
    Int Urol Nephrol. 2024 May 24. doi: 10.1007/s11255-024-04086.
    PubMed     Abstract available
    
    
    
64. ZHU W, Wu L, Xie W, Zhang G, et al
    Comparison of morbidity and mortality after radical cystectomy between individuals older and younger than 80 years: a systematic review and meta-analysis.
    Int Urol Nephrol. 2024;56:1525-1535.
    PubMed     Abstract available
    
    
    April 2024
65. BERNARDINO RM, Wettstein M, Garisto J, Fleshner NE, et al
    Editorial comment to the paper: RE: low cubilin/myeloperoxidase's ratio as a promising biomarker for prognosis of high grade T1 bladder cancer.
    Int Urol Nephrol. 2024 Apr 2. doi: 10.1007/s11255-024-04035.
    PubMed    
    
    
    
66. LI B, Lin Y, Yang Y, Wang Z, et al
    Patients with periodontitis might increase the risk of urologic cancers: a bidirectional two-sample Mendelian randomization study.
    Int Urol Nephrol. 2024;56:1243-1251.
    PubMed     Abstract available
    
    
    
67. JAKUS D, Solic I, Borovac JA, Situm M, et al
    The influence of the initial clinical presentation of upper tract urothelial carcinoma on histopathological tumor features.
    Int Urol Nephrol. 2024;56:1335-1341.
    PubMed     Abstract available
    
    
    March 2024
68. SILVA MEDEIROS M, Botelho de Carvalho LA, Alves M, Papoila A, et al
    Low Cubilin/Myeloperoxidase ratio as a promising biomarker for prognosis of high-grade T1 bladder cancer.
    Int Urol Nephrol. 2024 Mar 26. doi: 10.1007/s11255-024-03971.
    PubMed     Abstract available
    
    
    
69. ZHAI H, Wang Y, Chen Z, Wang Z, et al
    Clinicopathological characteristics, surgical treatments, and oncological outcomes of localized primary unifocal urothelial carcinoma involving the ureterovesical junction.
    Int Urol Nephrol. 2024;56:941-955.
    PubMed     Abstract available
    
    
    
70. MOEEN AM, Hameed DA, Mostafa MG, Shaban SH, et al
    Lymphadenectomy before and after radical cystectomy: does this affect the radicality? A prospective randomized comparative study.
    Int Urol Nephrol. 2024;56:965-972.
    PubMed     Abstract available
    
    
    February 2024
71. BRISUDA A, Hornak J, Zemlickova B, Hacek J, et al
    Intravesical thermochemotherapy in the treatment of high-risk and very high-risk non-muscle-invasive urothelial bladder cancer: a single-arm study.
    Int Urol Nephrol. 2024 Feb 8. doi: 10.1007/s11255-023-03924.
    PubMed     Abstract available
    
    
    
72. LI Y, Xu H, Lin T, Zhang J, et al
    Preoperative low plasma creatine kinase levels predict worse survival outcomes in bladder cancer after radical cystectomy.
    Int Urol Nephrol. 2024 Feb 5. doi: 10.1007/s11255-024-03957.
    PubMed     Abstract available
    
    
    
73. KACZMAREK K, Plage H, Furlano K, Hofbauer S, et al
    Loss of Upk1a and Upk1b expression is linked to stage progression in urothelial carcinoma of the bladder.
    Int Urol Nephrol. 2024;56:499-508.
    PubMed     Abstract available
    
    
    
74. BAHADORI A, Bray G, Rukin N
    Secondary tumours in orthotopic neobladder using isolated gut segment post radical cystectomy for urothelial carcinoma: a systematic review.
    Int Urol Nephrol. 2024;56:519-525.
    PubMed     Abstract available
    
    
    
75. WANG S, Wei Z, Shu H, Xu Y, et al
    Early diagnosis and prognostic potential of RAC3 in bladder tumor.
    Int Urol Nephrol. 2024;56:475-482.
    PubMed     Abstract available
    
    
    January 2024
76. WU J, Cheng X, Yang H, Xiao S, et al
    Geriatric nutritional risk index as a prognostic factor in elderly patients with non-muscle-invasive bladder cancer: a propensity score-matched study.
    Int Urol Nephrol. 2024 Jan 4. doi: 10.1007/s11255-023-03905.
    PubMed     Abstract available
    
    
    
77. SAITO T, Matsumoto K, Tanaka N, Fukumoto K, et al
    Prognostic impact of tumor ureteral invasion on recurrence after radical cystectomy.
    Int Urol Nephrol. 2024;56:129-135.
    PubMed     Abstract available
    
    
    November 2023
78. BEIJERT IJ, Hentschel AE, Brundl J, Comperat EM, et al
    Second TURB, restaging TURB or repeat TURB in primary T1 non-muscle invasive bladder cancer: impact on prognosis?
    Int Urol Nephrol. 2023 Nov 19. doi: 10.1007/s11255-023-03867.
    PubMed     Abstract available
    
    
    
79. GERCEK O, Keles I, Saritas TB, Koyuncu B, et al
    Effect of obturator nerve block during transurethral resection of bladder tumors on the disease recurrence, progression and surgery outcomes.
    Int Urol Nephrol. 2023;55:2765-2772.
    PubMed     Abstract available
    
    
    
80. MIYAKE M, Nishimura N, Nishioka Y, Fujii T, et al
    Clinical impact of the intensity of follow-up cystoscopy in patients with high-risk non-muscle-invasive bladder cancer.
    Int Urol Nephrol. 2023 Nov 1. doi: 10.1007/s11255-023-03851.
    PubMed     Abstract available
    
    
    
81. THAKKER PU, Refugia JM, Casals R, Able C, et al
    Stent-free rates in cutaneous ureterostomy urinary diversion after radical cystectomy.
    Int Urol Nephrol. 2023;55:2809-2814.
    PubMed     Abstract available
    
    
    October 2023
82. KOBERLE B, Usanova S, Piee-Staffa A, Heinicke U, et al
    Strong apoptotic response of testis tumor cells following cisplatin treatment.
    Int Urol Nephrol. 2023 Oct 27. doi: 10.1007/s11255-023-03825.
    PubMed     Abstract available
    
    
    
83. WEI C, Deng C, Dong R, Hou Y, et al
    Multi-omics analysis reveals critical metabolic regulators in bladder cancer.
    Int Urol Nephrol. 2023 Oct 26. doi: 10.1007/s11255-023-03841.
    PubMed     Abstract available
    
    
    
84. PAZIR Y, Esmeray A, Caglar U, Erbin A, et al
    Comparison of hyperthermic intravesical chemotherapy and Bacillus Calmette-Guerin therapy in high-risk non-muscle invasive bladder cancer: a matched-pair analysis.
    Int Urol Nephrol. 2023 Oct 25. doi: 10.1007/s11255-023-03849.
    PubMed     Abstract available
    
    
    
85. GERCEK O, Ulusoy K, Yazar VM, Topal K, et al
    Effects of delayed diagnosis on tumor size, stage and grade in bladder cancer.
    Int Urol Nephrol. 2023 Oct 17. doi: 10.1007/s11255-023-03829.
    PubMed     Abstract available
    
    
    
86. KHALIFA SE
    Immunohistochemical expression of CD117/KIT, HER2, and Erbeta in schistosomal and non-schistosomal urothelial carcinoma of Egyptian patients.
    Int Urol Nephrol. 2023;55:2473-2481.
    PubMed     Abstract available
    
    
    September 2023
87. KAYAR R, Bastug Y, Tokuc E, Topaktas R, et al
    Pan-immune-inflammation value as a prognostic tool for overall survival and disease-free survival in non-metastatic muscle-invasive bladder cancer.
    Int Urol Nephrol. 2023 Sep 29. doi: 10.1007/s11255-023-03812.
    PubMed     Abstract available
    
    
    
88. XIAOQIN Z, Zhouqi L, Huan P, Xinyi F, et al
    Development of a prognostic signature for immune-associated genes in bladder cancer and exploring potential drug findings.
    Int Urol Nephrol. 2023 Sep 23. doi: 10.1007/s11255-023-03796.
    PubMed     Abstract available
    
    
    
89. YOU C, Li Q, Qing L, Li R, et al
    Device-assisted intravesical chemotherapy versus bacillus Calmette-Guerin for intermediate or high-risk non-muscle invasive bladder cancer: a systematic reviewer and meta-analysis.
    Int Urol Nephrol. 2023 Sep 2. doi: 10.1007/s11255-023-03765.
    PubMed     Abstract available
    
    
    
90. OSMAN Y, Elawdy M, Taha DE, Zahran MH, et al
    Bladder perforation as a complication of transurethral resection of bladder tumors: the predictors, management, and its impact in a series of 1570 at a tertiary urology institute.
    Int Urol Nephrol. 2023;55:2161-2167.
    PubMed     Abstract available
    
    
    
91. WANG IK, Yu TM, Yen TH, Lin CL, et al
    Comparison of the risks of renal cell carcinoma or urothelial cancer between hemodialysis and peritoneal dialysis patients.
    Int Urol Nephrol. 2023;55:2267-2274.
    PubMed     Abstract available
    
    
    August 2023
92. ASSEM A, Kassem A, Sherif M, Lotfi A, et al
    Safety, feasibility, and quality of thulium laser en-bloc resection for treatment of non-muscle invasive bladder cancer.
    Int Urol Nephrol. 2023 Aug 28. doi: 10.1007/s11255-023-03752.
    PubMed     Abstract available
    
    
    
93. KIM SH, Choi BG, Oh JS, Chun HJ, et al
    Upper tract heparin instillation for maintenance of ureteral stent patency.
    Int Urol Nephrol. 2023;55:1893-1897.
    PubMed     Abstract available
    
    
    
94. OPPOLZER IA, Riester J, Buttner R, Burger M, et al
    Endocrine immune-related adverse events in patients with metastatic renal and urothelial cancer treated with immune checkpoint-inhibitors.
    Int Urol Nephrol. 2023;55:1943-1949.
    PubMed     Abstract available
    
    
    
95. WANG Z, Yang Z, Qu C, Li J, et al
    Natural killer cells strengthen antitumor activity of cisplatin by immunomodulation and ameliorate cisplatin-induced side effects.
    Int Urol Nephrol. 2023;55:1957-1970.
    PubMed     Abstract available
    
    
    July 2023
96. MOEEN AM, Faragallah MA, Zarzour MA, Elbehairy AA, et al
    Ileal conduit versus single stoma uretero-cutanoustomy after radical cystectomy in patients >/= 75 years; which technique is better? a prospective randomized comparative study.
    Int Urol Nephrol. 2023;55:1719-1726.
    PubMed     Abstract available
    
    
    June 2023
97. KABA M, Pirincci N, Demir M, Kaba S, et al
    The relationship between microRNAs and bladder cancer: are microRNAs useful to predict bladder cancer in suspicious patients?
    Int Urol Nephrol. 2023 Jun 20. doi: 10.1007/s11255-023-03666.
    PubMed     Abstract available
    
    
    
98. SLUSARCZYK A, Zapala P, Olszewska-Slusarczyk Z, Radziszewski P, et al
    The prediction of cancer-specific mortality in T1 non-muscle-invasive bladder cancer: comparison of logistic regression and artificial neural network: a SEER population-based study.
    Int Urol Nephrol. 2023 Jun 6. doi: 10.1007/s11255-023-03655.
    PubMed     Abstract available
    
    
    
99. YILMAZ H, Cinar NB, Avci IE, Akdas EM, et al
    Evaluation of comprehensive complication index versus Clavien-Dindo classification in prediction of overall survival after radical cystectomy.
    Int Urol Nephrol. 2023;55:1459-1465.
    PubMed     Abstract available
    
    
    May 2023
100. FU W, Liu D, Xiong Y, Liu C, et al
     The comparison between contrast-enhanced ultrasound and contrast-enhanced magnetic resonance imaging in diagnosing bladder urothelial carcinoma.
     Int Urol Nephrol. 2023;55:1073-1079.
     PubMed     Abstract available
     
     
     April 2023
101. NISHIHARA D, Kijima T, Arai K, Kamai T, et al
     Increased co-expression of stromal HHLA2 and fibroblast activation protein in upper tract urothelial carcinoma.
     Int Urol Nephrol. 2023;55:867-874.
     PubMed     Abstract available
     
     
     March 2023
102. GRIZZI F, Hegazi MAAA, Taverna G
     Letter to the editor re: "assessing bladder cancer prognosis through circulating tumor cell analysis and Ki-67 measurement".
     Int Urol Nephrol. 2023 Mar 3. doi: 10.1007/s11255-023-03538.
     PubMed    
     
     
     
103. DEWITT-FOY ME, Anele UA, Accioly JPE, Sharpe MG, et al
     Cancer risk in bladder diverticula: a large institutional analysis of risk and management.
     Int Urol Nephrol. 2023;55:541-546.
     PubMed     Abstract available
     
     
     
104. QIU Y, Zhang X, Dong Z, Zhang Y, et al
     Comparable survival benefits of partial ureterectomy to radical nephroureterectomy in non-metastatic ureter carcinoma: a population-matched study.
     Int Urol Nephrol. 2023;55:579-588.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum